10x Genomics, Inc. (TXG)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 70M 140M 210M Q1 '18: 27.4M Q2 '18: 31.7M Q3 '18: 36.6M Q4 '18: 50.6M Q1 '19: 53.6M Q2 '19: 55.8M Q3 '19: 61.2M Q4 '19: 75.3M Q1 '20: 71.9M Q2 '20: 42.9M Q3 '20: 71.8M Q4 '20: 112.2M Q1 '21: 105.8M Q2 '21: 115.8M Q3 '21: 125.3M Q4 '21: 143.5M Q1 '22: 114.5M Q2 '22: 114.6M Q3 '22: 131.1M Q4 '22: 156.2M Q1 '23: 134.3M Q2 '23: 146.8M Q3 '23: 153.6M Q4 '23: 184M Q1 '24: 141M Q2 '24: 153.1M Q3 '24: 151.7M Q4 '24: 165M Q1 '25: 154.9M Q2 '25: 172.9M Q3 '25: 149M Q4 '25: 166M Q1 '26: 150.8M Q2 '26: 151M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

0 50M 100M 150M Q1 '18: 23.4M Q2 '18: 27.2M Q3 '18: 31.4M Q4 '18: 35.7M Q1 '19: 39.6M Q2 '19: 40.8M Q3 '19: 45.7M Q4 '19: 58.7M Q1 '20: 56.8M Q2 '20: 32.9M Q3 '20: 57.4M Q4 '20: 93.3M Q1 '21: 88.8M Q2 '21: 110.9M Q3 '21: 100.8M Q4 '21: 115.9M Q1 '22: 89M Q2 '22: 86.9M Q3 '22: 100.7M Q4 '22: 119.4M Q1 '23: 98.4M Q2 '23: 99.6M Q3 '23: 95.5M Q4 '23: 115.8M Q1 '24: 92.9M Q2 '24: 104.2M Q3 '24: 106.4M Q4 '24: 111M Q1 '25: 105.4M Q2 '25: 125.1M Q3 '25: 100.3M Q4 '25: 113M Q1 '26: 106.2M Q2 '26: 112.5M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Income Quarterly

-450M -300M -150M 0 150M 300M 450M Q3 '18: -14.9M Q4 '18: -75M Q1 '19: -3M Q2 '19: -10.4M Q3 '19: -9.1M Q4 '19: -8.1M Q1 '20: -19.9M Q2 '20: -39.4M Q3 '20: -65.3M Q4 '20: -409.6M Q1 '21: -10.2M Q2 '21: -10.3M Q3 '21: -15.9M Q4 '21: -15.8M Q1 '22: -41.7M Q2 '22: -63.1M Q3 '22: -40M Q4 '22: -23.1M Q1 '23: -52M Q2 '23: -63.4M Q3 '23: -94.8M Q4 '23: -55.2M Q1 '24: -61.5M Q2 '24: -41.7M Q3 '24: -41.5M Q4 '24: -49.8M Q1 '25: -39.3M Q2 '25: 30.1M Q3 '25: -32.2M Q4 '25: -19.5M Q1 '26: -17M Q2 '26: -19.6M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income Quarterly

-450M -300M -150M 0 150M 300M 450M Q1 '18: -15.7M Q2 '18: -5.9M Q3 '18: -15.3M Q4 '18: -75.5M Q1 '19: -3.6M Q2 '19: -10.9M Q3 '19: -9.6M Q4 '19: -7.1M Q1 '20: -21.1M Q2 '20: -40.2M Q3 '20: -65.8M Q4 '20: -415.6M Q1 '21: -11.6M Q2 '21: -11.1M Q3 '21: -17.2M Q4 '21: -18.4M Q1 '22: -42.4M Q2 '22: -64.5M Q3 '22: -41.9M Q4 '22: -17.2M Q1 '23: -50.7M Q2 '23: -62.4M Q3 '23: -93M Q4 '23: -49M Q1 '24: -59.9M Q2 '24: -37.9M Q3 '24: -35.8M Q4 '24: -49M Q1 '25: -34.4M Q2 '25: 34.5M Q3 '25: -27.5M Q4 '25: -16.3M Q1 '26: -13.5M Q2 '26: -17.9M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

0 25M 50M 75M Q3 '18: 5.2M Q4 '18: 14.9M Q1 '19: 14M Q2 '19: 15M Q3 '19: 15.5M Q4 '19: 16.6M Q1 '20: 15.1M Q2 '20: 10.1M Q3 '20: 14.4M Q4 '20: 18.9M Q1 '21: 17.1M Q2 '21: 4.9M Q3 '21: 24.5M Q4 '21: 27.6M Q1 '22: 25.5M Q2 '22: 27.7M Q3 '22: 30.4M Q4 '22: 36.8M Q1 '23: 35.9M Q2 '23: 47.2M Q3 '23: 58.1M Q4 '23: 68.2M Q1 '24: 48.1M Q2 '24: 48.9M Q3 '24: 45.3M Q4 '24: 54.1M Q1 '25: 49.4M Q2 '25: 47.8M Q3 '25: 48.7M Q4 '25: 53M Q1 '26: 44.7M Q2 '26: 38.5M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating Cash Flow Quarterly

-150M -100M -50M 0 50M 100M 150M Q4 '18: -51M Q1 '19: 9.3M Q2 '19: 4.1M Q3 '19: 14.5M Q4 '19: 6.7M Q1 '20: -2.6M Q2 '20: -29.5M Q3 '20: -55.6M Q4 '20: -130.2M Q1 '21: -4.1M Q2 '21: 3.1M Q3 '21: -26.2M Q4 '21: 5.8M Q1 '22: -20.8M Q2 '22: -17M Q3 '22: -9.6M Q4 '22: 13.7M Q1 '23: -4.1M Q2 '23: -11.5M Q3 '23: -25.3M Q4 '23: 25.8M Q1 '24: -15.7M Q2 '24: 7.5M Q3 '24: 21.6M Q4 '24: -6.7M Q1 '25: 34.4M Q2 '25: 17.7M Q3 '25: 43.2M Q4 '25: 40.8M Q1 '26: 26.1M Q2 '26: 17M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Free Cash Flow Quarterly

-180M -120M -60M 0 60M 120M 180M Q4 '18: -53.4M Q1 '19: -49K Q2 '19: -9.1M Q3 '19: 848K Q4 '19: 144K Q1 '20: -10.7M Q2 '20: -36.3M Q3 '20: -56.1M Q4 '20: -151.5M Q1 '21: -42.9M Q2 '21: -11.4M Q3 '21: -46.4M Q4 '21: -21.8M Q1 '22: -48.9M Q2 '22: -44.2M Q3 '22: -46.1M Q4 '22: -26M Q1 '23: -8.7M Q2 '23: -36.9M Q3 '23: -40.5M Q4 '23: 22.3M Q1 '24: -18.6M Q2 '24: 4.6M Q3 '24: 17.8M Q4 '24: -9.5M Q1 '25: 32.5M Q2 '25: 16.1M Q3 '25: 42.5M Q4 '25: 39M Q1 '26: 24.5M Q2 '26: 15.4M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q1 '20: 96.8M Q2 '20: 99M Q3 '20: 101.3M Q1 '21: 108.7M Q2 '21: 109.9M Q3 '21: 110.9M Q1 '22: 113M Q2 '22: 113.6M Q3 '22: 114.1M Q1 '23: 115.6M Q2 '23: 116.7M Q3 '23: 117.7M Q1 '24: 119.4M Q2 '24: 120.1M Q3 '24: 120.7M Q1 '25: 122.6M Q2 '25: 124.5M Q3 '25: 125.5M Q1 '26: 128.3M Q2 '26: 130M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-9.00 -6.00 -3.00 0.00 3.00 6.00 9.00 Q4 '18: -8.21 Q1 '19: -7.23 Q2 '19: -7.48 Q3 '19: -6.68 Q4 '19: -1.35 Q1 '20: -1.32 Q2 '20: -1.03 Q3 '20: -1.35 Q4 '20: -5.37 Q1 '21: -5.26 Q2 '21: -4.95 Q3 '21: -4.45 Q4 '21: -0.53 Q1 '22: -0.80 Q2 '22: -1.27 Q3 '22: -1.49 Q4 '22: -1.47 Q1 '23: -1.53 Q2 '23: -1.49 Q3 '23: -1.91 Q4 '23: -2.17 Q1 '24: -2.23 Q2 '24: -2.02 Q3 '24: -1.53 Q4 '24: -1.53 Q1 '25: -1.31 Q2 '25: -0.71 Q3 '25: -0.63 Q4 '25: -0.35 Q1 '26: -0.17 Q2 '26: -0.59 Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.